Efficacy and Safety of Neoadjuvant Serplulimab Combined with Platinum-Based Doublet Chemotherapy and SBRT in Patients with Resectable or Potentially Resectable Stage IB–IIIB Small Cell Lung Cancer: A Phase 2 Study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 12e152bf00e4ad734b6116ea2a34695cce38b044
First added on: Oct 10, 2026